GLTO - Galecto - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

4.948M

Cash

53.25M

Avg Qtr Burn

-11.32M

Short % of Float

0.06%

Insider Ownership

0.40%

Institutional Own.

39.61%

Qtr Updated

03/31/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
GB0139 (inhaled galectin-3 inhibitor) Details Fibrosis, Pulmonary fibrosis, Lung disease Big Mover™ Suspected Mover™ Susp. Mover™	Phase 2/3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1211 (oral galectin-3 inhibitor) Details Non-small cell lung carcinoma, Fibrosis, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB2064 (oral LOXL2 inhibitor) Details Fibrosis, Myelofibrosis	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GB1211 (oral galectin-3 inhibitor) + TECENTRIQ Details Non-small cell lung carcinoma, Cancer, Fibrosis	Phase 2a Interim update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.